QQ客服 官方微博 反馈留言

	Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
	Zhang, Fangqiu; Wei, Lai; Xie, Qing; Hou, Jin Lin; Tang, Hong; Ning, Qin; Cheng, Jun; Nan, Yuemin; Zhang, Lunli; Li, Jun
刊名	HEPATOLOGY INTERNATIONAL
	2018
卷号	12期号:2
ISSN号	1936-0533
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3537942
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Zhang, Fangqiu,Wei, Lai,Xie, Qing,et al. Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study[J]. HEPATOLOGY INTERNATIONAL,2018,12(2).
APA	Zhang, Fangqiu.,Wei, Lai.,Xie, Qing.,Hou, Jin Lin.,Tang, Hong.,...&Duan, Zhongping.(2018).Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.HEPATOLOGY INTERNATIONAL,12(2).
MLA	Zhang, Fangqiu,et al."Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study".HEPATOLOGY INTERNATIONAL 12.2(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。